# Suprachoroidal Administration in Subjects With Metastases to the Choroid

Source: https://onco.cc/trials/nct06643884/  
OnCo record `nct06643884` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of AU-011 in advanced solid tumours, run by Aura Biosciences, now recruiting.

## Summary

Suprachoroidal Administration in Subjects With Metastases to the Choroid is a phase 2 interventional study registered as NCT06643884 by Aura Biosciences, with 24 participants planned, started 2024-12-16 and due to reach its primary completion in 2026-11-30. Interventions recorded: AU-011, SCS Microinjector and Laser.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06643884
- Phase: 2
- Setting: A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Belzupacap Sarotalocan (AU-011) With Suprachoroidal Administration in Subjects With Metastases to the Choroid
- Sponsor: Aura Biosciences
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT06643884: https://clinicaltrials.gov/study/NCT06643884

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Aura Biosciences](https://onco.cc/companies/aura-biosciences/)

---
JSON: https://onco.cc/api/v1/entities/nct06643884.json